PTN Key Statistics, Chart & Performance
The current stock price of PTN is 27.25 USD. In the past month the price increased by 152.32%. In the past year, price increased by 1357.22%.
PTN Latest News, Press Relases and Analysis
PTN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About PTN
Company Profile
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. The company is headquartered in Cranbury, New Jersey and currently employs 29 full-time employees. The firm is developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The firm's product development activities are focused on obesity, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity; ocular indications, including PL9643, an ophthalmic peptide solution for dry eye disease (DED), and ulcerative colitis, including PL8177, an oral peptide formulation. Its pipeline also includes PL7737 and PL9588. The firm's PL9588 is being developed as a topical treatment for glaucoma.
Company Info
PALATIN TECHNOLOGIES INC
4-B Cedar Brook Drive, Cedar Brook Corporate Center
Cranbury NEW JERSEY 08512 US
CEO: Carl Spana
Employees: 30
Phone: 16094952200
PALATIN TECHNOLOGIES INC / PTN FAQ
What does PTN do?
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. The company is headquartered in Cranbury, New Jersey and currently employs 29 full-time employees. The firm is developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The firm's product development activities are focused on obesity, including co-administration of bremelanotide with tirzepatide, a GLP-1 agonist for treatment of obesity; ocular indications, including PL9643, an ophthalmic peptide solution for dry eye disease (DED), and ulcerative colitis, including PL8177, an oral peptide formulation. Its pipeline also includes PL7737 and PL9588. The firm's PL9588 is being developed as a topical treatment for glaucoma.
Can you provide the latest stock price for PALATIN TECHNOLOGIES INC?
The current stock price of PTN is 27.25 USD. The price increased by 10.46% in the last trading session.
What is the dividend status of PALATIN TECHNOLOGIES INC?
PTN does not pay a dividend.
How is the ChartMill rating for PALATIN TECHNOLOGIES INC?
PTN has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists PTN stock?
PTN stock is listed on the NYSE Arca exchange.
How is the valuation of PALATIN TECHNOLOGIES INC (PTN) based on its PE ratio?
PALATIN TECHNOLOGIES INC (PTN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-59.5).
Can you provide the number of employees for PALATIN TECHNOLOGIES INC?
PALATIN TECHNOLOGIES INC (PTN) currently has 30 employees.
PTN Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PTN. When comparing the yearly performance of all stocks, PTN is one of the better performing stocks in the market, outperforming 99.97% of all stocks.
PTN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PTN. PTN has a bad profitability rating. Also its financial health evaluation is rather negative.
PTN Financial Highlights
Over the last trailing twelve months PTN reported a non-GAAP Earnings per Share(EPS) of -59.5. The EPS decreased by -109.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -625.34% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTN Forecast & Estimates
5 analysts have analysed PTN and the average price target is 52.53 USD. This implies a price increase of 92.77% is expected in the next year compared to the current price of 27.25.
For the next year, analysts expect an EPS growth of 98.1% and a revenue growth -100% for PTN